Currently, there are 151.42M common shares owned by the public and among those 137.98M shares have been available to trade.
The company’s stock has a 5-day price change of 0.04% and 18.37% over the past three months. TGTX shares are trading 42.62% year to date (YTD), with the 12-month market performance up to 134.01% higher. It has a 12-month low price of $9.81 and touched a high of $26.99 over the same period. TGTX has an average intraday trading volume of 3.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.20%, 3.56%, and 30.37% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of TG Therapeutics Inc (NASDAQ: TGTX) shares accounts for 59.93% of the company’s 151.42M shares outstanding.
It has a market capitalization of $4.05B and a beta (3y monthly) value of 2.18. The earnings-per-share (ttm) stands at -$0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.64% over the week and 5.29% over the month.
Earnings per share for the fiscal year are expected to decrease by -41.98%, and 1723.41% over the next financial year.
Looking at the support for the TGTX, a number of firms have released research notes about the stock. TD Cowen stated their Buy rating for the stock in a research note on October 29, 2024, with the firm’s price target at $50. Goldman coverage for the TG Therapeutics Inc (TGTX) stock in a research note released on August 02, 2023 offered a Neutral rating with a price target of $12. Jefferies was of a view on June 26, 2023 that the stock is Buy, while BofA Securities gave the stock Underperform rating on May 20, 2022, issuing a price target of $5. B. Riley Securities on their part issued Buy rating on February 23, 2022.
